Reinventing the discovery, development, and commercialization of new medicines (original) (raw)

We develop transformative medicines and technologies by building agile, focused companies called Vants.

• 10
  positive Phase 3 trials since 2019

Our model aligns incentives to drive fast, high-quality execution and rigorous capital allocation.

We employ technology across discovery, development, and commercialization.

Immunovant

Advancing potentially transformative therapies for autoimmune diseases

Priovant

Developing targeted therapies for patients with severe autoimmune disease

Pulmovant

Committed to transforming the lives of patients with pulmonary diseases

About Roivant

Read the latest from Roivant and the media.

Learn more about our work

Sign up for our latest announcements and upcoming presentations

Advancing medicines that matter

View our broad and differentiated pipeline of investigational drugs.